# Aeva Technologies, Inc.: financial statements, quarterly

AEVA · Nasdaq · CIK 1789029 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aeva.md) · [Financials](/companies/aeva/financials.md) · [Filings](/companies/aeva/filings.md) · [Insiders](/companies/aeva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aeva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0000950170-24-122684.md) | [1.6 d](/filings/0001193125-26-116518.md) | [2.1](/filings/0000950170-25-071752.md) | [2.0](/filings/0000950170-25-103384.md) | [2.3](/filings/0001193125-25-270405.md) | [2.7 d](/filings/0001193125-26-116518.md) | [3.4](/filings/0001193125-26-212597.md) | [5.5](/filings/0001193125-26-338179.md) | [3.6](/filings/0001193125-25-270405.md) | [5.6 d](/filings/0001193125-26-116518.md) | [6.3](/filings/0001193125-26-212597.md) | [6.1](/filings/0001193125-26-338179.md) |
| Cost of revenue | $m | [2.5](/filings/0000950170-24-122684.md) | [2.5 d](/filings/0001193125-26-116518.md) | [3.5](/filings/0000950170-25-071752.md) | [2.9](/filings/0000950170-25-103384.md) | [3.0](/filings/0001193125-25-270405.md) | [3.5 d](/filings/0001193125-26-116518.md) | [3.1](/filings/0001193125-26-212597.md) | [8.2](/filings/0001193125-26-338179.md) | [3.1](/filings/0001193125-25-270405.md) | [4.3 d](/filings/0001193125-26-116518.md) | [4.3](/filings/0001193125-26-212597.md) | [3.9](/filings/0001193125-26-338179.md) |
| Gross profit | $m | [(1.7)](/filings/0000950170-24-122684.md) | [(0.9) d](/filings/0001193125-26-116518.md) | [(1.4)](/filings/0000950170-25-071752.md) | [(0.8)](/filings/0000950170-25-103384.md) | [(0.7)](/filings/0001193125-25-270405.md) | [(0.8) d](/filings/0001193125-26-116518.md) | [0.3](/filings/0001193125-26-212597.md) | [(2.7)](/filings/0001193125-26-338179.md) | [0.4](/filings/0001193125-25-270405.md) | [1.3 d](/filings/0001193125-26-116518.md) | [1.9](/filings/0001193125-26-212597.md) | [2.2](/filings/0001193125-26-338179.md) |
| Research and development | $m | [23.8](/filings/0000950170-24-122684.md) | [26.2 d](/filings/0001193125-26-116518.md) | [25.0](/filings/0000950170-25-071752.md) | [26.2](/filings/0000950170-25-103384.md) | [27.1](/filings/0001193125-25-270405.md) | [24.3 d](/filings/0001193125-26-116518.md) | [21.6](/filings/0001193125-26-212597.md) | [22.8](/filings/0001193125-26-338179.md) | [22.2](/filings/0001193125-25-270405.md) | [18.9 d](/filings/0001193125-26-116518.md) | [22.8](/filings/0001193125-26-212597.md) | [24.9](/filings/0001193125-26-338179.md) |
| Operating income | $m | [(35.5)](/filings/0000950170-24-122684.md) | [(36.8) d](/filings/0001193125-26-116518.md) | [(37.3)](/filings/0000950170-25-071752.md) | [(48.9)](/filings/0000950170-25-103384.md) | [(37.9)](/filings/0001193125-25-270405.md) | [(34.2) d](/filings/0001193125-26-116518.md) | [(30.4)](/filings/0001193125-26-212597.md) | [(34.9)](/filings/0001193125-26-338179.md) | [(33.2)](/filings/0001193125-25-270405.md) | [(29.1) d](/filings/0001193125-26-116518.md) | [(35.1)](/filings/0001193125-26-212597.md) | [(34.6)](/filings/0001193125-26-338179.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-212597.md) | [0.0](/filings/0001193125-26-338179.md) | not reported | not reported | [1.2](/filings/0001193125-26-212597.md) | [1.2](/filings/0001193125-26-338179.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122684.md) | [0.0 d](/filings/0001193125-26-116518.md) | [0.0](/filings/0000950170-25-071752.md) | [0.1](/filings/0000950170-25-103384.md) | [0.0](/filings/0001193125-25-270405.md) | [0.0 d](/filings/0001193125-26-116518.md) | [0.1](/filings/0001193125-26-212597.md) | [0.1](/filings/0001193125-26-338179.md) | [0.1](/filings/0001193125-25-270405.md) | [0.1 d](/filings/0001193125-26-116518.md) | [0.0](/filings/0001193125-26-212597.md) | [0.1](/filings/0001193125-26-338179.md) |
| Net income | $m | [(33.2)](/filings/0000950170-24-122684.md) | [(45.0) d](/filings/0001193125-26-116518.md) | [(35.3)](/filings/0001193125-25-270405.md) | [(43.4)](/filings/0001193125-25-270405.md) | [(37.4)](/filings/0001193125-25-270405.md) | [(36.1) d](/filings/0001193125-26-116518.md) | [(34.9)](/filings/0001193125-26-338179.md) | [(193)](/filings/0001193125-26-338179.md) | [107](/filings/0001193125-25-270405.md) | [(25.3) d](/filings/0001193125-26-116518.md) | [(35.0)](/filings/0001193125-26-338179.md) | [(79.6)](/filings/0001193125-26-338179.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0000950170-24-122684.md) | not reported | [(0.67)](/filings/0000950170-25-071752.md) | [(0.82)](/filings/0000950170-25-103384.md) | [(0.70)](/filings/0001193125-25-270405.md) | not reported | [(0.64)](/filings/0001193125-26-212597.md) | [(3.49)](/filings/0001193125-26-338179.md) | [(0.52)](/filings/0001193125-25-270405.md) | not reported | [(0.56)](/filings/0001193125-26-212597.md) | [(1.23)](/filings/0001193125-26-338179.md) |
| Basic EPS | $ per share | [(0.75)](/filings/0000950170-24-122684.md) | not reported | [(0.67)](/filings/0000950170-25-071752.md) | [(0.82)](/filings/0000950170-25-103384.md) | [(0.70)](/filings/0001193125-25-270405.md) | not reported | [(0.64)](/filings/0001193125-26-212597.md) | [(3.49)](/filings/0001193125-26-338179.md) | [1.86](/filings/0001193125-25-270405.md) | not reported | [(0.56)](/filings/0001193125-26-212597.md) | [(1.23)](/filings/0001193125-26-338179.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [40.6](/filings/0000950170-23-063249.md) | [38.5](/filings/0000950170-25-042849.md) | [29.6](/filings/0000950170-24-056096.md) | [23.6](/filings/0000950170-24-094209.md) | [30.5](/filings/0000950170-24-122684.md) | [28.9](/filings/0001193125-26-116518.md) | [21.2](/filings/0000950170-25-071752.md) | [21.7](/filings/0000950170-25-103384.md) | [45.7](/filings/0001193125-25-270405.md) | [72.3](/filings/0001193125-26-338179.md) | [31.2](/filings/0001193125-26-212597.md) | [43.2](/filings/0001193125-26-338179.md) |
| Current assets | $m | [243](/filings/0000950170-23-063249.md) | [229](/filings/0000950170-25-042849.md) | [197](/filings/0000950170-24-056096.md) | [172](/filings/0000950170-24-094209.md) | [145](/filings/0000950170-24-122684.md) | [123](/filings/0001193125-26-116518.md) | [91.8](/filings/0000950170-25-071752.md) | [68.3](/filings/0000950170-25-103384.md) | [66.4](/filings/0001193125-25-270405.md) | [154](/filings/0001193125-26-338179.md) | [122](/filings/0001193125-26-212597.md) | [204](/filings/0001193125-26-338179.md) |
| Total assets | $m | [266](/filings/0000950170-23-063249.md) | [257](/filings/0000950170-25-042849.md) | [225](/filings/0000950170-24-056096.md) | [198](/filings/0000950170-24-094209.md) | [169](/filings/0000950170-24-122684.md) | [147](/filings/0001193125-26-116518.md) | [115](/filings/0000950170-25-071752.md) | [91.1](/filings/0000950170-25-103384.md) | [92.8](/filings/0001193125-25-270405.md) | [180](/filings/0001193125-26-338179.md) | [147](/filings/0001193125-26-212597.md) | [228](/filings/0001193125-26-338179.md) |
| Current liabilities | $m | [14.7](/filings/0000950170-23-063249.md) | [18.4](/filings/0000950170-25-042849.md) | [16.6](/filings/0000950170-24-056096.md) | [32.6](/filings/0000950170-24-094209.md) | [33.6](/filings/0000950170-24-122684.md) | [39.2](/filings/0001193125-26-116518.md) | [31.9](/filings/0000950170-25-071752.md) | [106](/filings/0000950170-25-103384.md) | [20.9](/filings/0001193125-25-270405.md) | [35.9](/filings/0001193125-26-338179.md) | [29.8](/filings/0001193125-26-212597.md) | [26.0](/filings/0001193125-26-338179.md) |
| Total liabilities | $m | [19.3](/filings/0000950170-23-063249.md) | [28.9](/filings/0000950170-25-042849.md) | [26.6](/filings/0000950170-24-056096.md) | [38.1](/filings/0000950170-24-094209.md) | [39.9](/filings/0000950170-24-122684.md) | [48.1](/filings/0001193125-26-116518.md) | [45.7](/filings/0000950170-25-071752.md) | [209](/filings/0000950170-25-103384.md) | [59.6](/filings/0001193125-25-270405.md) | [166](/filings/0001193125-26-338179.md) | [160](/filings/0001193125-26-212597.md) | [200](/filings/0001193125-26-338179.md) |
| Shareholders' equity | $m | [246](/filings/0000950170-24-122684.md) | [228](/filings/0001193125-26-116518.md) | [198](/filings/0001193125-25-270405.md) | [160](/filings/0001193125-25-270405.md) | [129](/filings/0001193125-25-270405.md) | [99.4](/filings/0001193125-26-338179.md) | [68.8](/filings/0001193125-26-338179.md) | [(118)](/filings/0001193125-26-338179.md) | [33.2](/filings/0001193125-25-270405.md) | [13.2](/filings/0001193125-26-338179.md) | [(12.4)](/filings/0001193125-26-338179.md) | [27.5](/filings/0001193125-26-338179.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(28.1) d](/filings/0000950170-24-122684.md) | [(27.3) d](/filings/0001193125-26-116518.md) | [(31.0)](/filings/0000950170-25-071752.md) | [(29.2) d](/filings/0000950170-25-103384.md) | [(25.9) d](/filings/0001193125-25-270405.md) | [(20.9) d](/filings/0001193125-26-116518.md) | [(30.8)](/filings/0001193125-26-212597.md) | [(29.8) d](/filings/0001193125-26-338179.md) | [(32.3) d](/filings/0001193125-25-270405.md) | [(22.1) d](/filings/0001193125-26-116518.md) | [(25.8)](/filings/0001193125-26-212597.md) | [(31.2) d](/filings/0001193125-26-338179.md) |
| Capital expenditure | $m | [1.0 d](/filings/0000950170-24-122684.md) | [2.7 d](/filings/0001193125-26-116518.md) | [1.6](/filings/0000950170-25-071752.md) | [0.8 d](/filings/0000950170-25-103384.md) | [0.5 d](/filings/0001193125-25-270405.md) | [2.1 d](/filings/0001193125-26-116518.md) | [0.5](/filings/0001193125-26-212597.md) | [1.4 d](/filings/0001193125-26-338179.md) | [1.3 d](/filings/0001193125-25-270405.md) | [1.5 d](/filings/0001193125-26-116518.md) | [2.2](/filings/0001193125-26-212597.md) | [0.2 d](/filings/0001193125-26-338179.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [218](/filings/0000950170-23-063249.md) | [43.9](/filings/0000950170-24-056096.md) | [44.1](/filings/0000950170-24-094209.md) | [44.6](/filings/0000950170-24-122684.md) | [52.7](/filings/0000950170-25-071752.md) | [53.0](/filings/0000950170-25-103384.md) | [53.7](/filings/0001193125-25-270405.md) | [54.8](/filings/0001193125-26-212597.md) | [55.2](/filings/0001193125-26-338179.md) | [61.1](/filings/0001193125-25-270405.md) | [62.8](/filings/0001193125-26-212597.md) | [64.7](/filings/0001193125-26-338179.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,705,758 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338179.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.